作者
Karolina Aberg, Daniel E Adkins, Jozsef Bukszar, Bradley T Webb, Stanley N Caroff, Del D Miller, Jonathan Sebat, Scott Stroup, Ayman H Fanous, Vladimir I Vladimirov, Joseph L McClay, Jeffrey A Lieberman, Patrick F Sullivan, Edwin JCG van den Oord
发表日期
2010/2/1
期刊
Biological psychiatry
卷号
67
期号
3
页码范围
279-282
出版商
Elsevier
简介
BACKGROUND
Understanding individual differences in the development of extrapyramidal side effects (EPS) as a response to antipsychotic therapy is essential to individualize treatment.
METHODS
We performed genomewide association studies to search for genetic susceptibility to EPS. Our sample consisted of 738 schizophrenia patients, genotyped for 492K single nucleotide polymorphisms (SNPs). We studied three quantitative measures of antipsychotic adverse drug reactions—the Simpson-Angus Scale (SAS) for Parkinsonism, the Barnes Akathisia Rating Scale, and the Abnormal Involuntary Movement Scale (AIMS)—as well as a clinical diagnosis of probable tardive dyskinesia.
RESULTS
Two SNPs for SAS, rs17022444 and rs2126709 with p = 1.2 × 10−10 and p = 3.8 × 10−7, respectively, and one for AIMS, rs7669317 with p = 7.7 × 10−8, reached genomewide significance (Q value < .1). rs17022444 and …
学术搜索中的文章
K Åberg, DE Adkins, J Bukszár, BT Webb, SN Caroff… - Biological psychiatry, 2010